Mitsubishi UFJ Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-268	Closed	-$35.4K	–	1655
2025 Q1	$35.4K	Buy	268 +162	+153%	+$20.2K	﹤0.01%	1055
2024 Q4	$8.87K	Hold	106	–	–	﹤0.01%	1319
2024 Q3	$7.76K	Hold	106	–	–	﹤0.01%	1319
2024 Q2	$7.26K	Hold	106	–	–	﹤0.01%	1282
2024 Q1	$7.33K	Hold	106	–	–	﹤0.01%	1234
2023 Q4	$7.36K	Hold	106	–	–	﹤0.01%	1202
2023 Q3	$5.52K	Buy	+106	New	+$6.17K	﹤0.01%	1242

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Mitsubishi UFJ Asset Management's ITCI Position: Q2 2025 in Review

Mitsubishi UFJ Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 268 shares — an estimated $35.4K sold.

Mitsubishi UFJ Asset Management first reported a position in ITCI in Q3 2023 and held it in 7 quarters. The position peaked at $35.4K in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Mitsubishi UFJ Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Mitsubishi UFJ Asset Management sold 268 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $35.4K.
Mitsubishi UFJ Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2023 and held it in 7 quarters.
Mitsubishi UFJ Asset Management's Intra-Cellular Therapies Inc. position peaked at $35.4K in Q1 2025.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.